Abstract:As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

Preliminary Application of 188rhenium As an Alternative Radionuclide for Treatment of Human Glioma after Baculovirus Transfected Sodium Iodide Symporter Gene Expression - A Comparing Study with 131Iodine

Human Sodium Iodide Transporter Gene-Mediated Imaging and Therapy of Mouse Glioma, Comparison Between 188re and 131I.

Preliminary Studies of Human Sodium Iodide Symporter Gene Imaging and Therapy Through 188re: A Human Glioma Study in Model Mice

Theranostic Studies of Human Sodium Iodide Symporter Imaging and Therapy Using 188re: a Human Glioma Study in Mice.

Use of Rhenium-188 for in Vivo Imaging and Treatment of Human Cervical Cancer Cells Transfected with Lentivirus Expressing Sodium Iodide Symporter.

Feasibility of a Novel Positive Feedback Effect of 131I-Promoted Bac-Egr1-hNIS Expression in Malignant Glioma Via Baculovirus

Feasibility of a novel positive feedback effect of 131I-promoted Bac–Egr1–hNIS expression in malignant glioma through baculovirus

Study On Molecular Imaging And Radionuclide Therapy Of Human Nasopharyngeal Carcinoma Cells Transfected With Baculovirus-Mediated Sodium/Iodine Symporter Gene

Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy.

Human Sodium/Iodide Symporter Gene Induced Iodine Uptake in Human Lung Adenocarcinoma Via Baculovirus

A Novel Ideal Radionuclide Imaging System for Non-invasively Cell Monitoring Built on Baculovirus Backbone by Introducing Sleeping Beauty Transposon

In Vivo Molecular Imaging And Radionuclide (I-131) Therapy Of Human Nasopharyngeal Carcinoma Cells Transfected With A Lentivirus Expressing Sodium Iodide Symporter

Experimental Study of Nasopharyngeal Carcinoma Radionuclide Imaging and Therapy Using Transferred Human Sodium/Iodide Symporter Gene

In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter

Baculovirus Vector-Mediated Transfer of Nis Gene into Colon Tumor Cells for Radionuclide Therapy

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

Transfected sodium iodide symporter gene following human telomerase reverse transcriptase promoter for tumor imaging of malignant glioma nude mice

The Glial Fibrillary Acidic Protein Promoter Directs Sodium/iodide Symporter Gene Expression for Radioiodine Therapy of Malignant Glioma

Baculovirus As An Ideal Radionuclide Reporter Gene Vector: A New Strategy For Monitoring The Fate Of Human Stem Cells In Vivo

Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene

Experimental Study of Dual Promoter Baculovirus-Mediated Tumor-Targeting Radioiodine Therapy